Search Results for: lrrk2

Parkinson's research

LRRK2 Drug Trial Show Promising Results

Monday, 8 January 2018

Denali Therapeutics has announced positive results from its first-in-human LRRK2 inhibitor clinical trial. The trial concluded that the experimental treatment is safe, and showed a greater than 90 percent inhibition of LRRK2 activity at peak drug levels while lowered the LRRK2…

New Research Confirms Role of LRRK2 in Immune Cells

Monday, 10 April 2017

Though associated with only a small percentage of total Parkinson’s cases, mutations of the LRRK2 gene are the greatest known genetic contributor to Parkinson’s disease (PD). Researchers are striving to understand the mechanisms of disease related to this mutation because…

Parkinson's research

Another Leap Forward for LRRK2 Development

Monday, 29 August 2016

Denali Therapeutics — a San Francisco biotech that launched last year focused on neurodegenerative diseases including Parkinson’s — recently announced it has licensed LRRK2 inhibitor compounds from Genentech. These drug candidates may address the dysfunction seen with LRRK2 mutations, the greatest…

Scientists Discover Potential Pathway of LRRK2 Dysfunction

Tuesday, 15 April 2014

Researchers from Johns Hopkins University have reported on a potential route through which mutations in the LRRK2 gene — the greatest known genetic contributor to Parkinson’s disease (PD) — lead to cell death. This finding comes as much of the…

Iwona Strycharska-OrzyMJFF Launches Access to LRRK2 Resources to Accelerate Discovery

MJFF Launches Access to LRRK2 Resources to Accelerate Discovery

Tuesday, 2 July 2013

In an effort to advance research and collaborate toward a cure, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is pioneering an innovative approach to accelerate drug development around the LRRK2 gene. Since 2009, MJFF has brought together international…

Scientists Find New Marker to Measure LRRK2 Activity

Scientists Find New Marker to Measure LRRK2 Activity

Tuesday, 18 December 2012

The protein leucine-rich repeat kinase 2, or LRRK2, is fast becoming a target of major interest for researchers looking to develop Parkinson’s disease (PD) drugs, for a couple of reasons: For one, mutations in the gene associated with LRRK2 are…

LRRK2 Physiology in Parkinson’s Disease

Thursday, 15 March 2012

  Date:            November 2011 Location:   Neuroscience Research Australia Prof Glenda Halliday & Dr Nic Dzamko Objective/Rationale: Mutations in the LRRK2 gene are a common cause of genetic Parkinson’s disease. LRRK2 is highly expressed in…

Brain

Study’s Measure Parkinson’s Progression

Thursday, 29 March 2018

Two recent papers outline the progression of Parkinson’s disease (PD) movement or motor symptoms in distinct study populations. While these findings do not provide an absolute picture of how one person will progress with PD, the results may help researchers…

17 New Genetic Variants Linked To Parkinson’s Disease

Sunday, 17 September 2017

A little more than 20 years ago, we thought Parkinson’s had no genetic connection. Today scientists have a growing list of genetic variants and mutations linked to the disease. While we’ve learned a lot in two decades, we know there…

Shake It UpDate - All the latest news in Parkinson's research and hopw you can help shake things up for a cure

Shake It UpDate September 2017

Saturday, 2 September 2017

In this Edition: New Parkinson’s Research Funded, Stem Cell Research, Solving the Parkinson’s Puzzle, Understanding Parkinson’s Video and more…     Dear Shake It Up Supporter, As we look to celebrate Father’s day this weekend take a moment to reflect on…

Nic Dzamko, PhD - Parkinson's research

New Project Funded: Inflammation in Parkinson’s Disease

Friday, 1 September 2017

Study Rationale: The contribution of inflammation to Parkinson’s disease (PD) is increasingly being recognized. However, the stage of the disease in which inflammation is prevalent and/or important remains unclear. Our recent work suggests that inflammation may be increased early in…

Parkinsons protein to head into space

Parkinson’s protein to take a trip into space

Sunday, 23 July 2017

The Michael J. Fox Foundation has partnered with the Center for the Advancement of Science in Space to send key Parkinson’s protein LRRK2 to the International Space Station for growth under microgravity conditions. “We’re thrilled that PD research has been…